Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.

SoftMedx Healthcare Limited
京玖醫療健康有限公司
(Incorporated in Hong Kong with limited liability)
(Stock Code: 648)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO PLACING OF NEW SHARES UNDER GENERAL MANDATE

Placing Agent
Advent Securities (Hong Kong) Limited

References are made to the announcement (the "**Announcement**") of SoftMedx Healthcare Limited (the "**Company**") dated 2 November 2026 in relation to the placing of new shares under general mandate. Unless defined otherwise, capitalised terms used herein shall have the same meaning as those defined in the Announcement.

This announcement is made to provide supplemental information in relation to the intended use of the net proceeds from the Placing.

BREAKDOWN AND EXPECTED TIME OF THE INTENDED USE OF PROCEEDS

The Company intends to apply the net proceeds from the Placing as follows:

(i) approximately HK$3.0 million or 52.9% of the net proceeds for the expansion and development of healthcare business in the Greater Bay Area (including but not limited to the payment of administrative expenses, rental, and staff costs), expected to be fully utilised by the first half of 2027;

(ii) approximately HK$2.67 million or 47.1% of the net proceeds will be used for general working capital of the Group (including but not limited to the payment of operating expenses of the Group), expected to be fully utilised by the first half of 2027.

REASONS FOR THE PLACING

As disclosed in the Company's interim results announcements for the six months ended 30 June 2026, the Company recorded bank balances and cash of approximately HK$26.5 million as at 30 June 2026. The Company considers that it has imminent funding needs to proceed with the Placing after considering that such cash has been allocated for the following purposes:

(i) approximately HK$20.5 million will be used for settlement of the Group's trade payable and operating expenses after 30 June 2026;

(ii) approximately HK$6.0 million will be used for the Group's procurement of medical and healthcare products for distribution.

Shareholders and potential investors should note that the completion of the Placing is subject to the fulfillment of the conditions as set out in the Placing Agreement and the Placing may or may not proceed. Shareholders and potential investors are reminded to exercise caution when dealing in the Shares.

By order of the Board
SoftMedx Healthcare Limited
Leung Ka Ho
Company Secretary

Hong Kong, 11 November 2026

As at the date of this announcement, the board of directors comprises Mr. Lin Pinzhuo as executive Director; and Mr. Ngok Ho Wai, Ms. Tang Cuihuen and Mr. Yiu Chun Wing as independent non-executive directors.